{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:39:40Z","timestamp":1773293980085,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.therap.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T16:02:01Z","timestamp":1474041721000},"page":"345-350","source":"Crossref","is-referenced-by-count":3,"title":["Cyam\u00e9mazine (Tercian\u00ae) et syndromes extrapyramidaux\u00a0: exploration des cas contenus dans la base nationale de pharmacovigilance"],"prefix":"10.1016","volume":"72","author":[{"given":"Charles","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Villier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Bougerol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.therap.2016.07.004_bib0005","first-page":"954","article-title":"Analyse des prescriptions de neuroleptiques dans cinq centres hospitaliers sp\u00e9cialis\u00e9s\u00a0: comparaison entre prescriptions hospitali\u00e8res et prescriptions de sortie","volume":"76","author":"Gury","year":"2000","journal-title":"Info Psychiatr"},{"issue":"2","key":"10.1016\/j.therap.2016.07.004_bib0010","first-page":"129","article-title":"Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia","volume":"28","author":"Brunot","year":"2002","journal-title":"Encephale"},{"issue":"1","key":"10.1016\/j.therap.2016.07.004_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1365-2125.2000.00108.x","article-title":"Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists","volume":"49","author":"Fourrier","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2016.07.004_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2016.07.004_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/WNL.31.2.132","article-title":"Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?","volume":"31","author":"Henderson","year":"1981","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.therap.2016.07.004_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2007.09.025","article-title":"Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes","volume":"578","author":"Benyamina","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2016.07.004_bib0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0006-2952(02)01515-0","article-title":"Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes","volume":"65","author":"Hameg","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2016.07.004_bib0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-011-2289-1","article-title":"Active cyamemazine metabolites in patients treated with cyamemazine (Tercian\u00ae): influence on cerebral dopamine D2\u00a0and serotonin 5-HT2A receptor occupancy as measured by positron emission tomography (PET)","volume":"217","author":"Hod\u00e9","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.therap.2016.07.004_bib0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2\u00a0occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.therap.2016.07.004_bib0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2\u00a0and serotonin2\u00a0pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.therap.2016.07.004_bib0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.psychres.2012.01.009","article-title":"Potential role of cortical 5-HT2A receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal","volume":"198","author":"Benyamina","year":"2012","journal-title":"Psychiatry Res"},{"issue":"7","key":"10.1016\/j.therap.2016.07.004_bib0060","first-page":"595","article-title":"Activit\u00e9 anxiolytique de la cyam\u00e9mazine\u00a0: r\u00f4le des r\u00e9cepteurs s\u00e9rotoninergiques","volume":"83","author":"Nuss","year":"2007","journal-title":"Info Psychiatr"},{"issue":"1","key":"10.1016\/j.therap.2016.07.004_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0166-4328(01)00238-8","article-title":"Cyamemazine as an anxiolytic drug on the elevated plus maze and light\/dark paradigm in mice","volume":"124","author":"Bourin","year":"2001","journal-title":"Behav Brain Res"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716311751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716311751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:21:59Z","timestamp":1749583319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716311751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0040595716311751"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.07.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}